Two leaders in science combine complementary best-in-class technologies for biologics manufacturing customers
It is the first integrated digital PCR solution ideal for oncology, cell and gene therapy development
Pluss Advanced Technologies (PLUSS), has led the growth of energy storage materials across applications. Their proprietary Phase Change Material has gained wide acceptance in the pharmaceutical, logistics and food industries. The varied demands of the industry during Covid-19 has brought its technology into focus. Samit Jain, MD, PLUSS in conversation with Thomas C Thottathil discusses trends and outlines his plans for the business
Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option
The company proposes to invest up to US $ 50 million, over a period of five years, starting from FY22, to support capability development of talent and technology
The WHO chief scientist Soumya Swaminathan tweeted on Oct. 17
Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting
The interim analysis showed that the MVC-COV1901 vaccine has a good safety profile and elicits promising neutralising antibody titres
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
Subscribe To Our Newsletter & Stay Updated
